Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading uniQure N.V. chart...

About the Company

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Exchange

NASDAQ

Website

uniqure.com

$3M

Total Revenue

588

Employees

$238M

Market Capitalization

-0.89

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $QURE News

uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization

20d ago, source: Yahoo Finance

Cash Position: uniQure NV (NASDAQ:QURE) reported a robust cash reserve of approximately $618 million as of December 31, 2023, expected to fund operations into Q2 2027. Revenue: Revenue for 2023 ...

uniQure NV QURE

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates

16d ago, source: Yahoo Finance

It's been a sad week for uniQure N.V. (NASDAQ:QURE), who've watched their investment drop 12% to US$5.59 in the week since the company reported its annual result. The results were mixed overall ...

Uniqure NV earnings missed by $0.05, revenue fell short of estimates

21d ago, source: Investing

Investing.com - Uniqure NV (NASDAQ: QURE) reported fourth quarter EPS of $-1.50, $0.05 worse than the analyst estimate of $-1.45. Revenue for the quarter came in at $2.31M versus the consensus ...

QURE uniQure N.V.

3d ago, source: Seeking Alpha

The chart has 1 X axis displaying Time. Data ranges from 2021-12-30 21:00:00 to 2033-12-30 21:00:00. The chart has 1 Y axis displaying values. Data ranges from -6.460890767 to 7.040788732.

Maintaining Hold on uniQure: Balancing Long-Term Potential Against Near-Term Uncertainties

19d ago, source: Business Insider

Begin your TipRanks Premium journey today. uniQure (QURE) Company Description: uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to ...

uniQure NV CEO Matthew Kapusta Sells 27,904 Shares

19d ago, source: Yahoo Finance

uniQure NV (NASDAQ:QURE), a company specializing in gene therapy, has reported a significant insider transaction. CEO and Managing Director Matthew Kapusta sold 27,904 shares of the company on ...

Maintaining Hold on uniQure Amid Regulatory Uncertainty and Financial Considerations

19d ago, source: Business Insider

Begin your TipRanks Premium journey today. uniQure (QURE) Company Description: uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to ...

uniQure N.V. (0EE0.L)

20d ago, source: Yahoo Finance

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history ...

Uniqure NV earnings missed by $0.05, revenue fell short of estimates

21d ago, source: Investing

Investing.com - Uniqure NV (NASDAQ: QURE) reported fourth quarter EPS of $-1.50, $0.05 worse than the analyst estimate of $-1.45. Revenue for the quarter came in at $2.31M versus the consensus ...

uniQure NV (QURE) Reports 2023 Financial Results Amid Strategic Reorganization

20d ago, source: Yahoo Finance

Cash Position: uniQure NV (NASDAQ:QURE) reported a robust cash reserve of approximately $618 million as of December 31, 2023, expected to fund operations into Q2 2027. Revenue: Revenue for 2023 ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...